132 related articles for article (PubMed ID: 26177744)
1. A new method for detection of tumor driver-dependent changes of protein sialylation in a colon cancer cell line reveals nectin-3 as TGFBR2 target.
Lee J; Warnken U; Schnölzer M; Gebert J; Kopitz J
Protein Sci; 2015 Oct; 24(10):1686-94. PubMed ID: 26177744
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116.
Lee J; Ballikaya S; Schönig K; Ball CR; Glimm H; Kopitz J; Gebert J
PLoS One; 2013; 8(2):e57074. PubMed ID: 23468914
[TBL] [Abstract][Full Text] [Related]
3. Reconstitution of TGFBR2 in HCT116 colorectal cancer cells causes increased LFNG expression and enhanced N-acetyl-d-glucosamine incorporation into Notch1.
Lee J; Katzenmaier EM; Kopitz J; Gebert J
Cell Signal; 2016 Aug; 28(8):1105-13. PubMed ID: 27156840
[TBL] [Abstract][Full Text] [Related]
4. Compensation of loss of protein function in microsatellite-unstable colon cancer cells (HCT116): a gene-dependent effect on the cell surface glycan profile.
Patsos G; André S; Roeckel N; Gromes R; Gebert J; Kopitz J; Gabius HJ
Glycobiology; 2009 Jul; 19(7):726-34. PubMed ID: 19293232
[TBL] [Abstract][Full Text] [Related]
5. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM
Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359
[TBL] [Abstract][Full Text] [Related]
6. TGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells.
Fricke F; Lee J; Michalak M; Warnken U; Hausser I; Suarez-Carmona M; Halama N; Schnölzer M; Kopitz J; Gebert J
Cell Commun Signal; 2017 Apr; 15(1):14. PubMed ID: 28376875
[TBL] [Abstract][Full Text] [Related]
7. Transforming Growth Factor β Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2.
de Miranda NF; van Dinther M; van den Akker BE; van Wezel T; ten Dijke P; Morreau H
Gastroenterology; 2015 Jun; 148(7):1427-37.e8. PubMed ID: 25736321
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of TGFBR2-Mediated Signaling Causes Upregulation of GDF-15 in HCT116 Colorectal Cancer Cells.
Lee J; Fricke F; Warnken U; Schnölzer M; Kopitz J; Gebert J
PLoS One; 2015; 10(6):e0131506. PubMed ID: 26114631
[TBL] [Abstract][Full Text] [Related]
9. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.
Grady WM; Willis JE; Trobridge P; Romero-Gallo J; Munoz N; Olechnowicz J; Ferguson K; Gautam S; Markowitz SD
Int J Cancer; 2006 Feb; 118(3):600-8. PubMed ID: 16108056
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Biswas S; Chytil A; Washington K; Romero-Gallo J; Gorska AE; Wirth PS; Gautam S; Moses HL; Grady WM
Cancer Res; 2004 Jul; 64(14):4687-92. PubMed ID: 15256431
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
12. miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer.
Li J; Liang H; Bai M; Ning T; Wang C; Fan Q; Wang Y; Fu Z; Wang N; Liu R; Zen K; Zhang CY; Chen X; Ba Y
PLoS One; 2015; 10(6):e0130194. PubMed ID: 26061281
[TBL] [Abstract][Full Text] [Related]
13. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
14. Concordant promoter methylation of transforming growth factor-beta receptor types I and II occurs early in esophageal squamous cell carcinoma.
Dong Z; Guo W; Guo Y; Kuang G; Yang Z
Am J Med Sci; 2012 May; 343(5):375-81. PubMed ID: 22314103
[TBL] [Abstract][Full Text] [Related]
15. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
[TBL] [Abstract][Full Text] [Related]
16. Tgf-beta signaling alterations and colon cancer.
Bellam N; Pasche B
Cancer Treat Res; 2010; 155():85-103. PubMed ID: 20517689
[TBL] [Abstract][Full Text] [Related]
17. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers.
Jung B; Smith EJ; Doctolero RT; Gervaz P; Alonso JC; Miyai K; Keku T; Sandler RS; Carethers JM
Int J Cancer; 2006 May; 118(10):2509-13. PubMed ID: 16380996
[TBL] [Abstract][Full Text] [Related]
18. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
Yamashita S; Takahashi S; McDonell N; Watanabe N; Niwa T; Hosoya K; Tsujino Y; Shirai T; Ushijima T
Cancer Res; 2008 Apr; 68(7):2112-21. PubMed ID: 18381416
[TBL] [Abstract][Full Text] [Related]
19. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation.
Sethi MK; Kim H; Park CK; Baker MS; Paik YK; Packer NH; Hancock WS; Fanayan S; Thaysen-Andersen M
Glycobiology; 2015 Oct; 25(10):1064-78. PubMed ID: 26085185
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R
Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
